CDKN3, a cyclin-dependent kinase inhibitor, is identified as a crucial therapeutic target for cervical cancer (52) and plays a role in the malignant advancement of pancreatic cancer by interacting with PSMD12 (53). The gene discussed is PSMD12; the disease is pancreatic neoplasm.